Market News AIOpen the app

Insmed shares the details from its earnings call for the second quarter of 2026.

ResultsRead the original at Benzinga
Good for INSM

Insmed's Brensocatib sales reached $309 million, up 49% from the prior quarter, and it raised its 2026 sales forecast to $1.25 billion–$1.4 billion. ARIKAYCE also grew, and cash flow is expected to turn positive by 2027, though those future results are not assured.

INSM · Insmed

AI read · Good for INSM

The AI's read

Continued Brensocatib demand could give Insmed a larger source of sales. ARIKAYCE also grew, and TPIP and possible new uses for its medicines offer more room to expand. Still, Japan approval, wider drug labels, and positive cash flow are future expectations, not completed results. The positive read rests on continued demand and progress toward those goals.

Get alerts for INSM

Follow Insmed (INSM) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for INSM
Free on the App Store and Google Play, or on the web.